The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
Clinical practice guideline addresses 6 emerging questions around COPD management.
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Zolgensma is an adeno-associated virus vector-based gene therapy.
In their presentation, Ahmad R. Sedaghat, MD, PhD and Stacey T. Gray, MD, FACS discuss both patient and physician perspectives for successful control of CRS.
Drugs in the Pipeline, News
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Topical glucocorticosteroids recommended over no treatment.